Ursolic acid potentializes conventional therapy in experimental leishmaniasis

Detalhes bibliográficos
Autor(a) principal: Jesus, Jéssica Adriana
Data de Publicação: 2020
Outros Autores: Da Silva, Thays Nicolli Fragoso, Yamamoto, Eduardo Seiji, Lago, João Henrique G., Laurenti, Márcia Dalastra, Passero, Luiz Felipe Domingues [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.3390/pathogens9100855
http://hdl.handle.net/11449/207887
Resumo: Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs.
id UNSP_246647a0a011362fb03c6e9ba3a9f2f0
oai_identifier_str oai:repositorio.unesp.br:11449/207887
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Ursolic acid potentializes conventional therapy in experimental leishmaniasisAmphotericin BCutaneous leishmaniasisGlucantimeLeishmaniasisTherapyVisceral leishmaniasisUrsolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs.Laboratory of Pathology of Infectious Diseases (LIM50) Department of Pathology Medical School of São Paulo University, Av. Dr. Arnaldo, 455Center of Natural and Human Sciences Federal University of ABC (UFABC), Avenida dos Estados 5001Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom HenriqueInstitute for Advanced Studies of Ocean São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178Institute of Biosciences São Paulo State University (UNESP) Praça Infante Dom HenriqueInstitute for Advanced Studies of Ocean São Paulo State University (UNESP), Rua João Francisco Bensdorp, 1178Universidade de São Paulo (USP)Universidade Federal do ABC (UFABC)Universidade Estadual Paulista (Unesp)Jesus, Jéssica AdrianaDa Silva, Thays Nicolli FragosoYamamoto, Eduardo SeijiLago, João Henrique G.Laurenti, Márcia DalastraPassero, Luiz Felipe Domingues [UNESP]2021-06-25T11:02:44Z2021-06-25T11:02:44Z2020-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1-14http://dx.doi.org/10.3390/pathogens9100855Pathogens, v. 9, n. 10, p. 1-14, 2020.2076-0817http://hdl.handle.net/11449/20788710.3390/pathogens91008552-s2.0-85094106349Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengPathogensinfo:eu-repo/semantics/openAccess2024-09-03T13:18:23Zoai:repositorio.unesp.br:11449/207887Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-09-03T13:18:23Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Ursolic acid potentializes conventional therapy in experimental leishmaniasis
title Ursolic acid potentializes conventional therapy in experimental leishmaniasis
spellingShingle Ursolic acid potentializes conventional therapy in experimental leishmaniasis
Jesus, Jéssica Adriana
Amphotericin B
Cutaneous leishmaniasis
Glucantime
Leishmaniasis
Therapy
Visceral leishmaniasis
title_short Ursolic acid potentializes conventional therapy in experimental leishmaniasis
title_full Ursolic acid potentializes conventional therapy in experimental leishmaniasis
title_fullStr Ursolic acid potentializes conventional therapy in experimental leishmaniasis
title_full_unstemmed Ursolic acid potentializes conventional therapy in experimental leishmaniasis
title_sort Ursolic acid potentializes conventional therapy in experimental leishmaniasis
author Jesus, Jéssica Adriana
author_facet Jesus, Jéssica Adriana
Da Silva, Thays Nicolli Fragoso
Yamamoto, Eduardo Seiji
Lago, João Henrique G.
Laurenti, Márcia Dalastra
Passero, Luiz Felipe Domingues [UNESP]
author_role author
author2 Da Silva, Thays Nicolli Fragoso
Yamamoto, Eduardo Seiji
Lago, João Henrique G.
Laurenti, Márcia Dalastra
Passero, Luiz Felipe Domingues [UNESP]
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade de São Paulo (USP)
Universidade Federal do ABC (UFABC)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Jesus, Jéssica Adriana
Da Silva, Thays Nicolli Fragoso
Yamamoto, Eduardo Seiji
Lago, João Henrique G.
Laurenti, Márcia Dalastra
Passero, Luiz Felipe Domingues [UNESP]
dc.subject.por.fl_str_mv Amphotericin B
Cutaneous leishmaniasis
Glucantime
Leishmaniasis
Therapy
Visceral leishmaniasis
topic Amphotericin B
Cutaneous leishmaniasis
Glucantime
Leishmaniasis
Therapy
Visceral leishmaniasis
description Ursolic acid (UA) is a triterpene with a broad array of pharmacological activities. In leishmaniasis, UA killed different species of parasites, and it was active in the experimental model of cutaneous and visceral leishmaniasis. Thus, the objective of this work was to study the therapeutic efficacy of the conventional drugs amphotericin B (AmB) or glucantime (Glu) combined with UA in experimental visceral and cutaneous leishmaniasis, respectively. L. (L.) infantuminfected hamsters were treated with AmB alone or combined with UA. L. (L.) amazonensis-infected BALB/c mice were treated with Glu alone or combined with UA. Animals were treated for 15 consecutive days by intraperitoneal or intralesional routes. Following one week after the last dose, the tissue parasitism and cellular immune responses were analyzed. Hamsters treated with 0.2 and 1.0 mg/kg of AmB plus 1.0 mg/kg of UA showed low hepatic and splenic parasitisms; however, AmB given as monotherapy did not reduce the number of viable parasites in the spleen of treated animals. In cutaneous leishmaniasis, Glu given as monotherapy was inactive at 2.0 mg/kg, showed mild activity at 10.0 mg/kg, and at 50.0 mg/kg was highly active at eliminating parasites in the skin. When animals were treated with Glu plus UA, higher leishmanicidal activity was observed in comparison to all groups treated with monotherapy schemes, and such activity was related to lesion improvement and upregulation of IFN-γ production. Altogether, data suggest that the association of drugs for the treatment of leishmaniasis can increase the efficiency of the treatment and decreasethe toxicity associated to the conventional drugs.
publishDate 2020
dc.date.none.fl_str_mv 2020-10-01
2021-06-25T11:02:44Z
2021-06-25T11:02:44Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.3390/pathogens9100855
Pathogens, v. 9, n. 10, p. 1-14, 2020.
2076-0817
http://hdl.handle.net/11449/207887
10.3390/pathogens9100855
2-s2.0-85094106349
url http://dx.doi.org/10.3390/pathogens9100855
http://hdl.handle.net/11449/207887
identifier_str_mv Pathogens, v. 9, n. 10, p. 1-14, 2020.
2076-0817
10.3390/pathogens9100855
2-s2.0-85094106349
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Pathogens
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1-14
dc.source.none.fl_str_mv Scopus
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv repositoriounesp@unesp.br
_version_ 1810021413272158208